Investing.com – Citizens lowered its price target on GH Research PLC (NASDAQ:GHRS) to $39 from $42 while maintaining a Market Outperform rating on the stock.
The firm adjusted its risk-adjusted, discounted cash flow-derived price target to reflect the company’s recent equity financing. GH Research reported first-quarter 2026 financial results and business updates this morning.
The company highlighted continued progress with its GH001 development program. Management reiterated plans to initiate a pivotal trial in late 2026 and continues to engage with the FDA on Phase 3 trial design.
The Phase 3 trial will likely largely replicate the Phase 2b design, according to management. GH Research ended the first quarter with approximately $267 million in cash. According to InvestingPro data, the company holds more cash than debt on its balance sheet, with a robust current ratio of 34.13, underscoring its strong liquidity position.
Citizens said the company is well funded to execute its global Phase 3 GH001 pivotal program. The stock has delivered impressive returns with a 108% gain over the past year and 75% year-to-date, trading at $22.21—near InvestingPro’s Fair Value estimate. Analysts remain optimistic, with price targets ranging from $25 to $70. For deeper insights including 10 additional ProTips and comprehensive financial health metrics, visit InvestingPro.
In other recent news, GH Research PLC has been active with several significant developments. The company announced an at-the-market equity offering, allowing for the sale of up to $200 million in ordinary shares through Stifel, Nicolaus & Company. Additionally, GH Research priced a public offering of 6,527,779 ordinary shares at $18 each, expecting to raise approximately $117.5 million in gross proceeds. The company also published results from its Phase 2b clinical trial for its depression treatment, GH001, with findings appearing in JAMA Psychiatry and Psychopharmacology Bulletin. Guggenheim has responded to these developments by raising its price target for GH Research to $34, maintaining a Buy rating. The company has scheduled its annual general meeting for June 25, 2026, in Dublin, providing shareholders with details and proxy materials. These recent activities highlight GH Research’s ongoing efforts in both financial and clinical progress.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.